Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $38.00 to $40.00. They now have a "buy" rating on the stock.
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates [Yahoo! Finance]
Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]